These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 18187583

  • 21. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
    Liao KS, Wei CL, Chen JC, Zheng HY, Chen WC, Wu CH, Wang TJ, Peng YS, Chang PY, Lin YW.
    Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
    [Abstract] [Full Text] [Related]

  • 22. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL, Chiu HC, Jian YJ, Jian YT, Chen CY, Syu JJ, Wo TY, Huang YJ, Tseng SC, Lin YW.
    Exp Cell Res; 2014 Apr 01; 322(2):345-54. PubMed ID: 24530475
    [Abstract] [Full Text] [Related]

  • 23. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
    Phuchareon J, McCormick F, Eisele DW, Tetsu O.
    Proc Natl Acad Sci U S A; 2015 Jul 21; 112(29):E3855-63. PubMed ID: 26150526
    [Abstract] [Full Text] [Related]

  • 24. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
    Eismann U, Oberschmidt O, Ehnert M, Fleeth J, Lüdtke FE, Struck S, Schulz L, Blatter J, Lahn MM, Ma D, Niyikiza C, Paoletti P, Hanauske AR.
    Int J Clin Pharmacol Ther; 2005 Dec 21; 43(12):567-9. PubMed ID: 16372519
    [No Abstract] [Full Text] [Related]

  • 25. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.
    Clin Cancer Res; 2003 Jun 21; 9(6):2316-26. PubMed ID: 12796401
    [Abstract] [Full Text] [Related]

  • 26. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
    Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F.
    Chemotherapy; 2008 Jun 21; 54(3):166-75. PubMed ID: 18560222
    [Abstract] [Full Text] [Related]

  • 27. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.
    Cell Death Dis; 2015 Aug 06; 6(8):e1850. PubMed ID: 26247735
    [Abstract] [Full Text] [Related]

  • 28. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A, Roca MS, Ciardiello C, Terranova-Barberio M, Vitagliano C, Ciliberto G, Mancini R, Di Gennaro E, Bruzzese F, Budillon A.
    Free Radic Biol Med; 2015 Dec 06; 89():287-99. PubMed ID: 26409771
    [Abstract] [Full Text] [Related]

  • 29. [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
    Deng QF, Su B, Zhao YM, Zhou CC.
    Zhonghua Zhong Liu Za Zhi; 2008 Nov 06; 30(11):813-6. PubMed ID: 19173824
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
    Markova B, Hähnel PS, Kasper S, Herbertz S, Schuler M, Breitenbuecher F.
    J Cancer Res Clin Oncol; 2012 Apr 06; 138(4):545-54. PubMed ID: 22203472
    [Abstract] [Full Text] [Related]

  • 32. Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
    Ko JC, Chiu HC, Syu JJ, Jian YJ, Chen CY, Jian YT, Huang YJ, Wo TY, Lin YW.
    Biochem Pharmacol; 2014 Mar 01; 88(1):119-27. PubMed ID: 24447935
    [Abstract] [Full Text] [Related]

  • 33. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 34. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, Jiang L.
    Oncol Res; 2013 Feb 01; 21(3):137-44. PubMed ID: 24512728
    [Abstract] [Full Text] [Related]

  • 35. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
    Coudray AM, Louvet C, Kornprobst M, Raymond E, André T, Tournigand C, Faivre S, De Gramont A, Larsen AK, Gespach C.
    Int J Oncol; 2005 Aug 01; 27(2):553-61. PubMed ID: 16010439
    [Abstract] [Full Text] [Related]

  • 36. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Aug 01; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 37. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM.
    Cancer Res; 2005 Apr 15; 65(8):3328-35. PubMed ID: 15833866
    [Abstract] [Full Text] [Related]

  • 38. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
    Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V.
    Cancer; 2013 Aug 01; 119(15):2754-64. PubMed ID: 23661337
    [Abstract] [Full Text] [Related]

  • 39. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
    Serizawa M, Takahashi T, Yamamoto N, Koh Y.
    J Thorac Oncol; 2013 Mar 01; 8(3):259-69. PubMed ID: 23334091
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.